Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/113335
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cordero Coma, Miguel | - |
dc.contributor.author | Calvo Río, Vanesa | - |
dc.contributor.author | Adán Civera, Alfredo | - |
dc.contributor.author | Blanco, Ricardo | - |
dc.contributor.author | Álvarez Castro, Carolina | - |
dc.contributor.author | Mesquida, Marina | - |
dc.contributor.author | Calleja, Sara | - |
dc.contributor.author | González-Gay, Miguel A. | - |
dc.contributor.author | Ruíz de Morales, José G. | - |
dc.date.accessioned | 2017-07-04T13:43:47Z | - |
dc.date.available | 2017-07-04T13:43:47Z | - |
dc.date.issued | 2014-05-28 | - |
dc.identifier.issn | 0962-9351 | - |
dc.identifier.uri | http://hdl.handle.net/2445/113335 | - |
dc.description.abstract | Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P - 0.009) and mean 1 mm central retinal thickness (317 versus 261.2 mu, P -0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Hindawi Publishing Corporation | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1155/2014/717598 | - |
dc.relation.ispartof | Mediators of Inflammation, 2014, vol. 2014 | - |
dc.relation.uri | https://doi.org/10.1155/2014/717598 | - |
dc.rights | cc-by (c) Cordero Coma, Miguel et al., 2014 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) | - |
dc.subject.classification | Uveïtis | - |
dc.subject.classification | Oftalmologia | - |
dc.subject.other | Uveitis | - |
dc.subject.other | Ophthalmology | - |
dc.title | Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 666315 | - |
dc.date.updated | 2017-07-04T13:43:47Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 24976689 | - |
Appears in Collections: | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
666315.pdf | 1.28 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License